Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies - PubMed

Comparative Study

Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies

John S Jarboe et al. Cancer Res. 2007.

Abstract

Glioblastoma multiforme is the most common primary malignant brain tumor and despite treatment with surgery, radiation, and chemotherapy, the median survival of patients with glioblastoma multiforme is approximately 1 year. Glioblastoma multiforme explants and cell lines have been reported to overexpress the interleukin-13 receptor alpha2 subunit (IL13Ralpha2) relative to nonneoplastic brain. Based on this finding, a recombinant cytotoxin composed of IL13 ligand and a truncated form of Pseudomonas aeruginosa exotoxin A (IL13-PE38QQR) was developed for the targeted treatment of glioblastoma multiforme tumors. In a recently completed phase III clinical trial, however, IL13-PE38QQR was found to be no more effective than an existing therapy in prolonging survival. To determine possible explanations for this result, we analyzed the relative expression levels of IL13Ralpha2 in glioblastoma multiforme and nonneoplastic brain specimens using publicly available oligonucleotide microarray databases, quantitative real-time reverse transcription PCR, and immunohistochemical staining. Increased expression of the IL13Ralpha2 gene relative to nonneoplastic brain was observed in 36 of 81 (44%) and 8 of 17 (47%) tumor specimens by microarray and quantitative real-time reverse transcription PCR analyses, respectively. Immunohistochemical staining of tumor specimens showed highly variable expression of IL13Ralpha2 protein both within and across specimens. These data indicate that prescreening of subjects may be of benefit in future trials of IL13Ralpha2 targeting therapies.

Similar articles

• Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

  Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Kahlon KS, et al. Cancer Res. 2004 Dec 15;64(24):9160-6. doi: 10.1158/0008-5472.CAN-04-0454. Cancer Res. 2004. PMID: 15604287

• Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.

  Kim K, Gwak HS, Han N, Hong EK, Choi BK, Lee S, Choi S, Park JH, Seok JH, Jeon Y, Cho H, Lee SJ, Lee Y, Nam KT, Song SW. Kim K, et al. Front Immunol. 2021 Nov 8;12:715000. doi: 10.3389/fimmu.2021.715000. eCollection 2021. Front Immunol. 2021. PMID: 34819930 Free PMC article.

• Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

  Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Thaci B, et al. Neuro Oncol. 2014 Oct;16(10):1304-12. doi: 10.1093/neuonc/nou045. Epub 2014 Apr 10. Neuro Oncol. 2014. PMID: 24723564 Free PMC article. Review.

• Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.

  Liang R, Wu C, Liu S, Zhao W. Liang R, et al. Drug Deliv. 2022 Dec;29(1):1620-1630. doi: 10.1080/10717544.2022.2075986. Drug Deliv. 2022. PMID: 35612318 Free PMC article. Review.

Cited by

• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.

  Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC. Brown CE, et al. Clin Cancer Res. 2015 Sep 15;21(18):4062-72. doi: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9. Clin Cancer Res. 2015. PMID: 26059190 Free PMC article. Clinical Trial.

• Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.

  Lian X, Kats D, Rasmussen S, Martin LR, Karki A, Keller C, Berlow NE. Lian X, et al. Acta Neuropathol Commun. 2021 May 17;9(1):88. doi: 10.1186/s40478-021-01184-9. Acta Neuropathol Commun. 2021. PMID: 34001278 Free PMC article.

• Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo.

  Li J, Shi L, Zhang X, Kang X, Wen Y, Qian H, Zhou Y, Xu W, Zhang Y, Wu M, Yin Z. Li J, et al. Cancer Gene Ther. 2010 Nov;17(11):771-9. doi: 10.1038/cgt.2010.34. Epub 2010 Jul 2. Cancer Gene Ther. 2010. PMID: 20596089 Free PMC article.

• Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

  Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Candolfi M, et al. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6. doi: 10.1073/pnas.1008261107. Epub 2010 Oct 28. Proc Natl Acad Sci U S A. 2010. PMID: 21030678 Free PMC article.

• Targeted Delivery of Nanoparticulate Cytochrome C into Glioma Cells Through the Proton-Coupled Folate Transporter.

  Kucheryavykh YV, Davila J, Ortiz-Rivera J, Inyushin M, Almodovar L, Mayol M, Morales-Cruz M, Cruz-Montañez A, Barcelo-Bovea V, Griebenow K, Kucheryavykh LY. Kucheryavykh YV, et al. Biomolecules. 2019 Apr 18;9(4):154. doi: 10.3390/biom9040154. Biomolecules. 2019. PMID: 31003476 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information